---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-061524"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:53:56.035727+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Inhibikase Therapeutics awards stock options to CEO and CFO with performance vesting tied to Phase 2a study

## Summary
- CEO Milton H. Werner granted options for 315,000 shares at $0.7390; 105,000 subject to performance vesting.
- CFO Joseph Frattaroli granted options for 135,000 shares at $0.7390; 45,000 subject to performance vesting.
- Performance milestones tied to completion and release of IKT-148009 Phase 2a study in Parkinson's disease.
- Remaining options subject to time vesting under 2020 Equity Incentive Plan.

## SEC filing metadata
- accession: 0001193125-23-061524
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312523061524/0001193125-23-061524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312523061524/d410993d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-061524
- JSON: https://secwatch.observer/filing/0001193125-23-061524.json
- Plain text: https://secwatch.observer/filing/0001193125-23-061524.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.